# Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

> **NCT04655313** · PHASE2 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Psoriasis
- Plaque Psoriasis

## Interventions

- **DRUG:** ARQ-151 cream 0.3%

## Key facts

- **NCT ID:** NCT04655313
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-30
- **Primary completion:** 2022-01-12
- **Final completion:** 2022-01-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655313, "Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04655313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*